Canada Anti-Hypertensive Drugs Market is anticipated to register a substantial rise over the forecast period, thanks to the growing consumption of
junk food, lack of proper healthy and balanced diet, leading sedentary
lifestyle along with lack of proper sleep due to irregular work shifts across
the region.
Additionally, the increasing
prevalence of hypertension is the major factor propelling the growth of the Canada
anti-hypertensive drugs market during the forecast period. Also, growing awareness of
the complications of high blood pressure and expansion of antihypertensive drug
research is expected to increase the demand for anti-hypertensive drugs,
thereby boosting the Canada anti-hypertensive drugs market through 2028. The
increasing number of initiatives by private and governmental organizations are also
expected to increase the demand for anti-hypertensive drugs, supporting the market’s
growth. For instance, in 2021, 25%
of the Canada population under (50-64 year age people) were suffering from
hypertension.
According to a report by the
Canadian Chronic Disease Surveillance System, hypertension affects
approximately 7.4 million adults in Canada, which is equivalent to 21.6% of the
adult population. The prevalence of hypertension increases with age, with
approximately 60% of Canadians over the age of 60 being affected by
hypertension. In terms of gender, the
prevalence of hypertension is similar in men and women. However, women are more
likely to be aware of their hypertension and receive treatment for it than men.
Aging Population
The aging population is a significant
driver of the growth of the Canada Anti-Hypertensive Drugs market. As people
age, the risk of developing hypertension increases, making the condition more
prevalent among older adults. According to Statistics Canada, the prevalence of
hypertension increases from 8.8% in people aged between 20 and 39 years to
59.1% in people aged between 60 and 79 years. As a result, the demand for
anti-hypertensive drugs has been steadily increasing in recent years. Older
adults are more likely to have multiple health conditions and take multiple
medications, including anti-hypertensive drugs.
Additionally, older adults are more
likely to have a higher income, making them more willing and able to pay for
prescription medications. Furthermore,
the aging population in Canada is expected to continue growing in the coming
years, driven by a combination of factors such as increasing life expectancy
and declining birth rates. This demographic shift is expected to lead to a
further increase in the demand for anti-hypertensive drugs over the next few
years.
According to a report by the Canadian
Institute for Health Information (CIHI), anti-hypertensive drugs were the
second most commonly prescribed medication class in Canada in 2019, accounting
for 12% of all prescriptions. The
use of hypertensive drugs in Canada is increasing. According to the same CIHI
report, the number of prescriptions for antihypertensive drugs increased by
3.7% between 2018 and 2019, which is higher than the overall increase in
prescription drug use in Canada during the same period.
Increased Healthcare Spending
Increased healthcare spending is another
important driver of the growth of the Canada Anti-Hypertensive Drugs market.
The Canadian government has been increasing its healthcare spending to meet the
growing demand for medical services, including the treatment of hypertension. As a result of this increased
spending, there has been an improvement in the availability and accessibility
of healthcare services, including the availability of anti-hypertensive drugs.
This has contributed significantly to the growth of the market, as more people
are able to receive the medications, they need to manage their condition.
Moreover, increased healthcare spending
has also led to the development of more sophisticated healthcare
infrastructure, such as hospitals and clinics, which are better equipped to
diagnose and treat hypertension. This has led to an increase in the number of
people seeking medical help for this medical condition, aiding the market. The most prescribed classes
of antihypertensive drugs in Canada are ACE inhibitors, angiotensin receptor
blockers (ARBs), calcium channel blockers, and diuretics. These medications are
used to lower blood pressure and reduce the risk of cardiovascular events in
patients with hypertension.
Download Free Sample Report
Rise in Lifestyle Diseases
The rise in lifestyle diseases is a key
driver of the growth of the Canada Anti-Hypertensive Drugs market. Lifestyle
diseases, such as obesity, diabetes, and hypertension, are becoming more
prevalent in Canada, driven by several factors, such as sedentary lifestyles,
unhealthy diets, and an aging population. As hypertension is a common co-morbidity
with other lifestyle diseases, the prevalence of hypertension is also
increasing, leading to a surge in the demand for anti-hypertensive drugs. This
trend is expected to continue in the coming years, as the prevalence of
lifestyle diseases is projected to increase due to changing demographics and
lifestyle factors.
Additionally, the rising awareness about
the importance of managing hypertension and lifestyle diseases has led to an
increase in the number of people seeking medical help for their condition. This
has contributed to the growth of the market, as more people are being diagnosed
with hypertension and prescribed anti-hypertensive drugs. Pharmaceutical companies
operating in the Canada anti-hypertensive drugs market are likely to benefit
from this trend in the coming years, as the demand for these drugs is expected
to continue to grow. However, they will need to innovate and develop new and
more effective drugs to meet the evolving needs of patients with hypertension
and lifestyle diseases.
Development of Novel Drugs
The development of new drugs is a
critical factor that influences the growth of the Canada anti-hypertensive
drugs market. The introduction of new and more effective drugs can drive the
demand for anti-hypertensive drugs by providing better treatment options for
patients. Pharmaceutical companies are
investing in research and development to create new drugs that offer improved
efficacy, safety, and ease of use. New drugs that can control hypertension with
fewer side effects, simpler dosing regimens, and longer durations of action are
expected to be well-received by patients and healthcare providers. Moreover, the introduction of
new drugs can also increase competition among pharmaceutical companies, leading
to lower prices and improved access for patients. This can also stimulate
innovation and encourage companies to develop more effective drugs.
Another recent development in the market
is the increasing usage of telemedicine for the management of hypertension.
Telemedicine allows patients to consult with their healthcare provider
remotely, which can improve access to care for patients who may have difficulty
traveling to a clinic or hospital. Telemedicine can also be a more convenient
option for patients and may reduce the burden on healthcare providers. As a
result, many healthcare providers are taking up telemedicine to manage hypertension,
and this trend is expected to continue to grow in the coming years.
Increased Awareness of Hypertension
The awareness of hypertension is an
important driving factor in the Canada anti-hypertensive drugs market.
Hypertension is a widespread condition that affects millions of Canadians, and
awareness about the importance of managing hypertension has been steadily
increasing in recent years. The
surge in the awareness of hypertension among consumers has led to more people
seeking medical help for their condition, which in turn has contributed to the
growth of the market. More people are being diagnosed with hypertension and are
prescribed anti-hypertensive drugs as a result of this increased awareness.
In addition to this, the increased
awareness of hypertension has led to a greater emphasis on lifestyle
modifications, such as exercise and a healthy diet, to manage the condition.
This has led to an increase in the number of people taking a proactive approach
to managing their hypertension, which has contributed to the growth of the
market.
Furthermore, the rise in awareness among
consumers regarding hypertension has also led to more research into the
condition and the development of new and more effective treatment options. This
has helped to stimulate innovation in the Canada anti-hypertensive drugs market
and contributed to the development of new drugs.
Recent Developments
- Entresto
(sacubitril/valsartan) - This drug was approved by Health Canada in 2019 for
the treatment of heart failure with reduced ejection fraction. It is a
combination of two drugs that work together to improve the heart's ability to
pump blood and reduce the risk of hospitalization due to heart failure.
- Qternmet
XR (dapagliflozin/saxagliptin/metformin hydrochloride) - This drug was launched
in Canada in 2020 for the treatment of type 2 diabetes and hypertension. It
combines three drugs in one tablet to help control blood sugar levels and lower
blood pressure.
- Mylan-Telmisartan
HCTZ (telmisartan/hydrochlorothiazide) - This drug was launched in Canada in
2021 to treat hypertension. It is a combination of two drugs that work together
to lower blood pressure and reduce the risk of heart attack and stroke.
Market
Segmentation
The Canada anti-hypertensive
drugs market can be segmented by therapeutic class, type, distribution channel,
and region. Based on therapeutic class, the Canada anti-hypertensive drugs market
can be segmented into diuretics,
ACE inhibitors, ARBs, calcium channel blockers, beta-adrenergic blockers, renin
inhibitors, vasodilators, and others. Based on type, Canada anti-hypertensive
drugs market can be divided into primary hypertension and secondary
hypertension. Based on distribution channel, the anti-hypertensive drugs market
in Canada can be segmented into retail pharmacies, hospital pharmacies, and e-commerce
websites & online drug stores.
Market Players
Pfizer Canada Inc., Merck Canada Inc., AstraZeneca Canada
Inc, Novartis Pharmaceuticals Canada Inc, Sanofi-Aventis Canada Inc.,
Boehringer Ingelheim (Canada) Ltd., Bristol-Myers Squibb Canada., Takeda Canada
Inc., Teva Canada Ltd., and Servier Canada Inc. are some of the leading players
operating in the Canada anti-hypertensive drugs market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 – 2021
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative
Units
|
Revenue in USD Million, Volume in Units, and CAGR for 2018-2022
and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, volume forecast, company share, competitive landscape, growth
factors, and trends
|
|
Segments
Covered
|
By Therapeutic
Class
By Type
By
Distribution Channel
By Region
|
|
Regional
Scope
|
Ontario
region; Quebec region; Alberta region; British Columbia region; Saskatchewan
and Manitoba region; Rest of Canada
|
|
Key
Companies Profiled
|
Pfizer Canada Inc., Merck Canada Inc., AstraZeneca Canada Inc,
Novartis Pharmaceuticals Canada Inc, Sanofi-Aventis Canada Inc., Boehringer
Ingelheim (Canada) Ltd., Bristol-Myers Squibb Canada., Takeda Canada Inc.,
Teva Canada Ltd., Servier Canada Inc.
|
|
Customization
Scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and Purchase Options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through Email (We can also provide the editable
version of the report in PPT/Word format on special request)
|
Report Scope:
In this report, the Canada
anti-hypertensive drugs market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
·
Canada Anti-Hypertensive Drugs Market, By Therapeutic Class:
o Diuretics
o ACE inhibitors
o ARBs
o Calcium Channel Blockers
o Beta Adrenergic Blockers
o Renin Inhibitors
o Vasodilators
o Others
·
Canada Anti-Hypertensive Drugs Market, By Type:
o Primary Hypertension
o Secondary Hypertension
·
Canada Anti-Hypertensive Drugs Market, By Distribution Channel:
o Retail Pharmacy
o Hospital Pharmacy
o E-commerce Websites & Online
Drug Stores
·
Canada Anti-Hypertensive Drugs Market, By Region:
o Ontario Region
o Quebec Region
o Alberta region
o British Columbia region
o Saskatchewan and Manitoba region
o Rest of Canada
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the Canada Anti-Hypertensive Drugs Market.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
The Canada anti-hypertensive drugs market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]